ZENTALIS PHARMACEUTICALS, INC. Zentalis Pharmaceuticals, Inc. announced the appointment of Luke Walker, M.D., to its Board of Directors as a Class II director, effective May 24, 2024. Dr. Walker has also been appointed to serve on the Audit Committee of the Board (the ?Audit Committee?). Luke Walker, M.D., 52, has served as a member of Board of Directors since May 2024.
Dr. Walker has been the Chief Medical Officer of Harpoon Therapeutics, Inc., or Harpoon, an oncology-focused biopharmaceutical company focused on the development of T-cell engagers in oncology, since October 2022. Harpoon was acquired by Merck & Co., Inc., Rahway, NJ in March 2024. From March 2018 to September 2022, Dr. Walker served as Vice President, Clinical Development for Seagen, Inc. (fka Seattle Genetics, Inc.), where he initially led the development of TUKYSA (tucatinib) and later, a portfolio of early stage programs. Prior to that, from 2011 to 2018, Dr. Walker held various roles in clinical development at Cascadian Therapeutics Inc. (fka Oncothyreon, Inc.), a biopharmaceutical company that was acquired by Seagen, culminating in his role as Senior Vice President, Clinical Development.
Dr. Walker served as a medical oncologist and hematologist at Providence Regional Medical Center, Everett, WA, from 2007 to 2011 and at The Everett Clinic, Center for Cancer Care, from 2005 to 2007. Dr. Walker is a current Diplomate of the American Board of Internal Medicine in Medical Oncology, with prior board certifications in Hematology and Internal Medicine. He completed fellowships in bone marrow and stem cell transplantation, and hematology and medical oncology at Oregon Health Sciences University.
Dr. Walker received his M.D. from the University of Oklahoma Health Sciences Center and his B.A. in letters and French from the University of Oklahoma. Dr. Walker also completed the Stanford Graduate School of Business LGBTQ Executive Leadership Program in 2017. The company believe Dr. Walker's extensive experience in the biopharmaceutical industry, particularly in oncology, makes him qualified to serve on Board.
